Get the Stockscreener App
0.379
21.14%
-0.1016
After Hours:
.40
0.021
+5.54%
Mereo Biopharma Group Plc Adr stock is traded at $0.379, with a volume of 38.66M.
It is down -21.14% in the last 24 hours and down -81.60% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$0.4806
Open:
$0.45
24h Volume:
38.66M
Relative Volume:
4.22
Market Cap:
$60.31M
Revenue:
$10.00M
Net Income/Loss:
$-29.47M
P/E Ratio:
-1.895
EPS:
-0.2
Net Cash Flow:
$-21.55M
1W Performance:
+2.29%
1M Performance:
-81.60%
6M Performance:
-86.79%
1Y Performance:
-89.92%
1-Day Range:
$0.3691
$0.5073
1-Week Range:
$0.333
$0.59
52-Week Range:
$0.20
$3.84
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.379 | 76.48M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-25 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
This Mereo BioPharma Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Sahm
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures - Investing.com UK
Ultragenyx stock plummets 43% after setrusumab fails in Phase III trial - Investing.com India
Mereo BioPharma stock plummets after failed Phase 3 trials By Investing.com - Investing.com South Africa
Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com India
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials By Investing.com - Investing.com India
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta - Investing News Network
Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows - Sahm
Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC - Defense World
Mereo BioPharma Group’s (MREO) “Buy” Rating Reaffirmed at BTIG Research - Defense World
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
683 Capital Management LLC Decreases Stock Holdings in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO) - MarketBeat
Investors Buy High Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO) - MarketBeat
It makes sense and dollars to buy Mereo Biopharma Group Plc ADR (MREO) stock - setenews.com
Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data - Investing.com UK
This trade activity should not be overlooked: Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc (MREO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Equities Analysts Issue Forecasts for MREO FY2025 Earnings - Defense World
A better buy-in window may exist right now for Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Wall Street analysts’ outlook for Mereo Biopharma Group Plc ADR (MREO) - Setenews
FY2025 EPS Forecast for Mereo BioPharma Group Cut by Analyst - Defense World
Leerink Partnrs Has Negative Forecast for MREO Q4 Earnings - MarketBeat
Leerink Partnrs Issues Negative Forecast for MREO Earnings - Defense World
A new trading data show Mereo Biopharma Group Plc ADR (MREO) is showing positive returns. - setenews.com
[8-K] Mereo BioPharma Group plc Reports Material Event | MREO SEC FilingForm 8-K - Stock Titan
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights - Investing News Network
Mereo Biopharma Group Plc ADR (MREO) looking to reclaim success with recent performance - Setenews
Tangible book value per share of Mereo BioPharma Group plc Sponsored ADR – HAN:MAH0 - TradingView
Aberdeen Group plc Has $8.21 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Rating of “Buy” by Brokerages - Defense World
An analyst sees good growth prospects for Chime Financial Inc (CHYM) - Setenews
Atle Fund Management AB Has $2.07 Million Stock Position in Mereo BioPharma Group plcSponsored ADR $MREO - MarketBeat
Goldman Sachs Group Inc. Raises Stake in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):